Patents Assigned to LIVERPOOL SCHOOL OF TROPICAL MEDICINE
-
Patent number: 11518760Abstract: The present invention relates to compounds of Formulae (I) and (II) as defined herein, and salts and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formulae (I) and (II), and to the use of compounds of Formulae (I) and (II) in the treatment or prevention of filarial worm infection, as well as other diseases or conditions in which filarial worm infection is implicated.Type: GrantFiled: January 17, 2018Date of Patent: December 6, 2022Assignees: Liverpool School of Tropical Medicine, The University of Liverpool, Eisai R&D Management Co., Ltd.Inventors: Stephen A. Ward, Mark J. Taylor, Paul M. O'Neill, Weiqian David Hong, Farid Benayoud
-
Patent number: 10888174Abstract: Mosquito bed net assembly 10a-h includes a mosquito bed net (12) impregnated with a first insecticide and a barrier member 16a-h located above an upper surface (14) of the bed net (12) and being impregnated with a second insecticide. In use, bed net assembly 16a-h increases the likelihood of delivering a lethal dosage of insecticide to mosquitoes flying in frequently-visited areas of a bed net, without increased attendant health risk to a user.Type: GrantFiled: October 23, 2014Date of Patent: January 12, 2021Assignee: LIVERPOOL SCHOOL OF TROPICAL MEDICINEInventor: Philip John McCall
-
Patent number: 10238677Abstract: The present invention pertains to prevention of and/or treatment for filariasis. In particular, the present invention pertains to the use of tylosin A and its analogs and derivatives to prevent or treat filarial worm infection and/or diseases associated with filarial worm infection. The present invention also pertains to pharmaceutical compositions comprising tylosin A or an analog or derivative thereof for use in preventing or treating filarial worm infection and/or diseases associated with filarial worm infection.Type: GrantFiled: January 8, 2016Date of Patent: March 26, 2019Assignees: LIVERPOOL SCHOOL OF TROPICAL MEDICINE, ABBVIE INC.Inventors: Thomas W. Von Geldern, Dale J. Kempf, Kennan C. Marsh, Mark John Taylor, Stephen Andrew Ward, Louise Ford, Joseph Turner
-
Publication number: 20170368088Abstract: The present invention pertains to prevention of and/or treatment for filariasis. In particular, the present invention pertains to the use of tylosin A and its analogs and derivatives to prevent or treat filarial worm infection and/or diseases associated with filarial worm infection. The present invention also pertains to pharmaceutical compositions comprising tylosin A or an analog or derivative thereof for use in preventing or treating filarial worm infection and/or diseases associated with filarial worm infection.Type: ApplicationFiled: January 8, 2016Publication date: December 28, 2017Applicants: AbbVie Inc., Liverpool School of Tropical MedicineInventors: Thomas W. VON GELDERN, Dale J. KEMPF, Kennan C. MARSH, Mark John TAYLOR, Stephen Andrew WARD, Louis FORD, Joseph TURNER
-
Patent number: 9556494Abstract: Provided is a method for identifying human immunodeficiency virus (HIV) in a sample. The invention involves use of a plurality of fluorescently labeled oligonucleotide probes and flow cytometry to detect the presence or absence of HIV in macrophages that are obtained from a mucosal surface. The invention is particularly useful for detecting HIV infection prior to seroconversion.Type: GrantFiled: November 21, 2012Date of Patent: January 31, 2017Assignees: Cornell University, Liverpool School of Tropical MedicineInventors: David G. Russell, Henry Mwandumba, Kondwani Jambo
-
Publication number: 20150218236Abstract: A method for treatment of a mammalian subject for an autoimmune or inflammatory disease, the method comprising: administering to the mammalian subject an effective amount of a polymeric protein comprising five, six or seven polypeptide monomer units; wherein each polypeptide monomer unit comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; wherein each immunoglobulin G heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin G heavy chain constant region of an adjacent polypeptide monomer unit; wherein the polymeric protein does not comprise a further immunomodulatory portion; or an antigen portion that causes antigen-specific immunosuppression when administered to the mammalian subject.Type: ApplicationFiled: October 17, 2012Publication date: August 6, 2015Applicant: LIVERPOOL SCHOOL OF TROPICAL MEDICINEInventor: Richard John Pleass
-
Publication number: 20130023551Abstract: A compound having the formula (I) wherein ring A represents a substituted or unsubstituted monocyclic or multicyclic ring; m=any positive integer; n=0-5; X?CH and Y?—C(O)NR1R2, —NR1R2 or —S(O)2R4, where R1, R2 and R4 are each individually selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted amine, substituted or unsubstituted carbocyclic ring, substituted or unsubstituted heterocyclic ring, or any combination thereof, or R1 and R2 are linked so as to form part of a substituted or unsubstituted heterocyclic ring, or X?N and Y?—S(O)2R3 or —C(O)R3, where R3 is selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted amine, substituted or unsubstituted carbocyclic ring, substituted or unsubstituted heterocyclic ring or any combination thereof.Type: ApplicationFiled: May 18, 2012Publication date: January 24, 2013Applicant: LIVERPOOL SCHOOL OF TROPICAL MEDICINEInventors: Richard Amewu, Paul Michael O'Neill, Andrew Stachulski, Gemma Ellis, Stephen Andrew Ward